OS THERAPIES INCORPORATED Interest Expense
OS THERAPIES INCORPORATED (OSTX) reported Interest Expense of $828.76 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-20.
Discontinued
us-gaap:InterestExpense · last filed 2024-05-20
- OS THERAPIES INCORPORATED interest expense for the quarter ending 2024-03-31 was $828.76K, a 3.73% increase year-over-year.
- OS THERAPIES INCORPORATED interest expense for the quarter ending 2023-03-31 was $798.94K.
| Period end | Interest Expense 3 month |
|---|---|
| 2024-03-31 | $828.76K 10-Q · filed 2024-05-20 |
| 2023-03-31 | $798.94K 10-Q · filed 2024-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |